AstraZeneca Historical Income Statement

AZN Stock

USD 67.62 0.42 0.63%

Historical analysis of AstraZeneca PLC income statement accounts such as Interest Expense of 1.7 B, Total Revenue of 24.2 B or Gross Profit of 19.9 B can show how well AstraZeneca PLC ADR performed in making a profits. Evaluating AstraZeneca PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AstraZeneca PLC's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC ADR is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About AstraZeneca Income Statement Analysis

AstraZeneca PLC ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AstraZeneca PLC shareholders. The income statement also shows AstraZeneca investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

AstraZeneca PLC Income Statement Chart

At this time, AstraZeneca PLC's Tax Provision is very stable compared to the past year. As of the 1st of December 2024, Interest Income is likely to grow to about 342.8 M, while Total Revenue is likely to drop about 24.2 B.

Interest Expense Total Revenue Gross Profit Other Operating Expenses Operating Income Selling And Marketing Expenses

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts AstraZeneca PLC ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of AstraZeneca PLC ADR minus its cost of goods sold. It is profit before AstraZeneca PLC operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AstraZeneca PLC ADR. It is also known as AstraZeneca PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from AstraZeneca PLC ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of AstraZeneca PLC ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most accounts from AstraZeneca PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Interest Expense	1.3B	1.3B	1.6B	1.7B
Depreciation And Amortization	4.1B	5.3B	4.9B	5.2B

Interest Expense Depreciation And Amortization

AstraZeneca PLC income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Cost Of Revenue	Minority Interest	Selling And Marketing Expenses	Net Income From Continuing Ops	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.05	0.67	0.65	0.66	0.17	-0.21	0.66	0.33	0.8	0.2	0.13	0.18	0.14	0.76	0.66	-0.79	-0.07	0.37	0.12	-0.78	-0.14	0.54	-0.47
Interest Expense	0.05		0.43	0.43	0.42	0.11	0.33	0.75	0.25	0.59	0.01	-0.86	0.09	-0.23	0.33	0.29	0.4	-0.3	0.37	0.13	0.12	0.21	0.47	-0.46
Total Revenue	0.67	0.43		0.98	0.96	0.39	0.19	0.75	0.64	0.77	0.33	-0.24	0.4	0.06	0.89	0.8	-0.32	0.11	0.19	-0.17	-0.51	0.24	0.64	-0.15
Gross Profit	0.65	0.43	0.98		0.89	0.52	0.34	0.73	0.75	0.75	0.47	-0.18	0.53	0.19	0.83	0.67	-0.31	-0.04	0.32	-0.01	-0.44	0.16	0.52	-0.22
Other Operating Expenses	0.66	0.42	0.96	0.89		0.1	-0.06	0.76	0.4	0.77	0.05	-0.35	0.12	-0.2	0.95	0.89	-0.29	0.23	0.06	-0.31	-0.54	0.32	0.75	-0.09
Operating Income	0.17	0.11	0.39	0.52	0.1		0.86	0.15	0.92	0.14	0.99	0.33	0.99	0.83	0.03	-0.07	-0.17	-0.31	0.41	0.34	-0.04	-0.21	-0.2	-0.18
Ebit	-0.21	0.33	0.19	0.34	-0.06	0.86		0.08	0.82	0.0	0.82	0.05	0.84	0.65	-0.19	-0.29	0.32	-0.38	0.35	0.31	0.43	-0.11	-0.3	-0.14
Research Development	0.66	0.75	0.75	0.73	0.76	0.15	0.08		0.36	0.96	0.1	-0.55	0.14	-0.11	0.74	0.7	-0.18	-0.27	0.47	0.09	-0.38	0.04	0.79	-0.65
Ebitda	0.33	0.25	0.64	0.75	0.4	0.92	0.82	0.36		0.37	0.89	0.17	0.92	0.67	0.3	0.14	-0.15	-0.25	0.41	0.25	-0.06	-0.07	-0.01	-0.19
Total Operating Expenses	0.8	0.59	0.77	0.75	0.77	0.14	0.0	0.96	0.37		0.12	-0.39	0.15	-0.07	0.82	0.72	-0.35	-0.25	0.5	0.12	-0.48	-0.04	0.77	-0.68
Income Before Tax	0.2	0.01	0.33	0.47	0.05	0.99	0.82	0.1	0.89	0.12		0.43	0.99	0.87	-0.01	-0.1	-0.24	-0.32	0.41	0.36	-0.06	-0.28	-0.23	-0.19
Total Other Income Expense Net	0.13	-0.86	-0.24	-0.18	-0.35	0.33	0.05	-0.55	0.17	-0.39	0.43		0.35	0.61	-0.28	-0.26	-0.54	0.07	-0.12	0.08	-0.16	-0.4	-0.45	0.2
Net Income	0.18	0.09	0.4	0.53	0.12	0.99	0.84	0.14	0.92	0.15	0.99	0.35		0.78	0.05	-0.04	-0.17	-0.27	0.41	0.26	-0.04	-0.25	-0.2	-0.15
Income Tax Expense	0.14	-0.23	0.06	0.19	-0.2	0.83	0.65	-0.11	0.67	-0.07	0.87	0.61	0.78		-0.21	-0.29	-0.35	-0.39	0.26	0.58	-0.07	-0.24	-0.34	-0.19
Selling General Administrative	0.76	0.33	0.89	0.83	0.95	0.03	-0.19	0.74	0.3	0.82	-0.01	-0.28	0.05	-0.21		0.87	-0.43	0.16	0.17	-0.2	-0.62	0.22	0.74	-0.21
Cost Of Revenue	0.66	0.29	0.8	0.67	0.89	-0.07	-0.29	0.7	0.14	0.72	-0.1	-0.26	-0.04	-0.29	0.87		-0.39	0.35	-0.07	-0.47	-0.67	0.3	0.9	-0.1
Minority Interest	-0.79	0.4	-0.32	-0.31	-0.29	-0.17	0.32	-0.18	-0.15	-0.35	-0.24	-0.54	-0.17	-0.35	-0.43	-0.39		0.01	-0.16	-0.18	0.83	0.18	-0.24	0.23
Selling And Marketing Expenses	-0.07	-0.3	0.11	-0.04	0.23	-0.31	-0.38	-0.27	-0.25	-0.25	-0.32	0.07	-0.27	-0.39	0.16	0.35	0.01		-0.78	-0.83	-0.19	0.45	0.04	0.8
Net Income From Continuing Ops	0.37	0.37	0.19	0.32	0.06	0.41	0.35	0.47	0.41	0.5	0.41	-0.12	0.41	0.26	0.17	-0.07	-0.16	-0.78		0.6	-0.1	-0.41	0.07	-0.8
Tax Provision	0.12	0.13	-0.17	-0.01	-0.31	0.34	0.31	0.09	0.25	0.12	0.36	0.08	0.26	0.58	-0.2	-0.47	-0.18	-0.83	0.6		0.04	-0.29	-0.27	-0.62
Interest Income	-0.78	0.12	-0.51	-0.44	-0.54	-0.04	0.43	-0.38	-0.06	-0.48	-0.06	-0.16	-0.04	-0.07	-0.62	-0.67	0.83	-0.19	-0.1	0.04		-0.11	-0.51	0.13
Net Interest Income	-0.14	0.21	0.24	0.16	0.32	-0.21	-0.11	0.04	-0.07	-0.04	-0.28	-0.4	-0.25	-0.24	0.22	0.3	0.18	0.45	-0.41	-0.29	-0.11		0.27	0.43
Reconciled Depreciation	0.54	0.47	0.64	0.52	0.75	-0.2	-0.3	0.79	-0.01	0.77	-0.23	-0.45	-0.2	-0.34	0.74	0.9	-0.24	0.04	0.07	-0.27	-0.51	0.27		-0.37
Extraordinary Items	-0.47	-0.46	-0.15	-0.22	-0.09	-0.18	-0.14	-0.65	-0.19	-0.68	-0.19	0.2	-0.15	-0.19	-0.21	-0.1	0.23	0.8	-0.8	-0.62	0.13	0.43	-0.37

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	171.9K	2.9B	4.1B	5.3B	4.9B	5.2B
Interest Expense	1.4B	1.3B	1.3B	1.3B	1.6B	1.7B
Total Revenue	24.4B	26.6B	37.4B	44.4B	45.8B	24.2B
Gross Profit	19.5B	21.3B	25.0B	32.0B	37.8B	19.9B
Other Operating Expenses	21.2B	21.5B	36.4B	40.6B	37.6B	19.0B
Operating Income	2.9B	5.2B	1.1B	3.8B	8.2B	5.0B
Ebit	7.0B	4.7B	573M	3.4B	8.5B	5.8B
Research Development	6.0B	6.0B	9.7B	9.8B	11.0B	11.6B
Ebitda	7.0B	7.6B	4.7B	8.6B	13.4B	7.6B
Total Operating Expenses	16.3B	16.2B	23.9B	28.2B	29.6B	31.1B
Income Before Tax	1.5B	3.9B	(265M)	2.5B	6.9B	4.5B
Total Other Income Expense Net	(1.4B)	(1.2B)	(1.3B)	(1.3B)	(1.3B)	(1.2B)
Net Income	1.3B	3.2B	112M	3.3B	6.0B	3.5B
Income Tax Expense	321M	772M	(380M)	(792M)	938M	729.2M
Selling General Administrative	11.7B	11.7B	15.7B	19.0B	17.5B	11.9B
Cost Of Revenue	4.9B	5.3B	12.4B	12.4B	8.0B	6.4B
Net Income Applicable To Common Shares	1.3B	3.2B	112M	3.3B	3.0B	3.2B
Minority Interest	1.5B	16M	(3M)	(5M)	(6M)	(5.7M)
Selling And Marketing Expenses	11.8B	11.7B	15.7B	19.0B	539M	512.1M
Net Income From Continuing Ops	1.2B	3.1B	115M	3.3B	6.0B	6.3B
Tax Provision	321M	772M	(380M)	(792M)	938M	984.9M
Interest Income	774M	87M	43M	95M	301M	342.8M
Net Interest Income	(1.2B)	(1.2B)	(1.3B)	(1.3B)	(1.3B)	(1.4B)
Reconciled Depreciation	3.8B	3.1B	6.5B	5.5B	4.9B	4.8B

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

0.78	HLN	Haleon plc	Pair Corr
0.9	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.81	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.81	ANRO	Alto Neuroscience,	Pair Corr

Moving against AstraZeneca Stock

0.83	AXP	American Express Fiscal Year End 24th of January 2025	Pair Corr
0.78	FNMFO	Federal National Mortgage	Pair Corr
0.77	TRV	The Travelers Companies Fiscal Year End 17th of January 2025	Pair Corr
0.47	ITCL	Banco Ita Chile	Pair Corr
0.44	KB	KB Financial Group	Pair Corr

The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.

The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:

How To Invest In AstraZeneca

Details

Is AstraZeneca Stock a good investment?

Details

What is AstraZeneca PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.034

Dividend Share

2.97

Earnings Share

2.08

Revenue Per Share

2.7424

Quarterly Revenue Growth

0.18

The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Historical Income Statement

About AstraZeneca Income Statement Analysis

AstraZeneca PLC Income Statement Chart

Interest Expense

Total Revenue

Gross Profit

Other Operating Expenses

Operating Income

AstraZeneca PLC income statement Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC income statement Accounts

Pair Trading with AstraZeneca PLC

Moving together with AstraZeneca Stock

Moving against AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 0.99	Operating Income
Net Income	+ 0.99	Operating Income
Net Income	+ 0.99	Income Before Tax
Gross Profit	+ 0.98	Total Revenue
Other Operating Expenses	+ 0.96	Total Revenue
Total Operating Expenses	+ 0.96	Research Development

Total Other Income Expense Net	- 0.86	Interest Expense
Tax Provision	- 0.83	Selling And Marketing Expenses
Extraordinary Items	- 0.8	Net Income From Continuing Ops
Minority Interest	- 0.79	Depreciation And Amortization
Net Income From Continuing Ops	- 0.78	Selling And Marketing Expenses
Interest Income	- 0.78	Depreciation And Amortization